company background image
HNSA

Hansa Biopharma OM:HNSA Stock Report

Last Price

kr82.50

Market Cap

kr3.7b

7D

-5.1%

1Y

-27.9%

Updated

15 Aug, 2022

Data

Company Financials +
HNSA fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

HNSA Stock Overview

Hansa Biopharma AB (publ), a biopharmaceutical company, develops immunomodulatory treatments for enabling transplants and rare immunoglobulin G (IgG)-mediated autoimmune conditions, gene therapy, and cancer using its proprietary enzyme technology platform.

Hansa Biopharma AB (publ) Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Hansa Biopharma
Historical stock prices
Current Share Pricekr82.50
52 Week Highkr138.30
52 Week Lowkr47.24
Beta1.04
1 Month Change51.38%
3 Month Change46.02%
1 Year Change-27.95%
3 Year Change-52.40%
5 Year Change-51.90%
Change since IPO650.00%

Recent News & Updates

Shareholder Returns

HNSASE BiotechsSE Market
7D-5.1%0.7%0.9%
1Y-27.9%-20.3%-20.9%

Return vs Industry: HNSA underperformed the Swedish Biotechs industry which returned -20.6% over the past year.

Return vs Market: HNSA underperformed the Swedish Market which returned -21.8% over the past year.

Price Volatility

Is HNSA's price volatile compared to industry and market?
HNSA volatility
HNSA Average Weekly Movement16.1%
Biotechs Industry Average Movement8.9%
Market Average Movement7.2%
10% most volatile stocks in SE Market12.6%
10% least volatile stocks in SE Market4.5%

Stable Share Price: HNSA is more volatile than 90% of Swedish stocks over the past 3 months, typically moving +/- 16% a week.

Volatility Over Time: HNSA's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of Swedish stocks.

About the Company

FoundedEmployeesCEOWebsite
2007145Søren Tulstruphttps://www.hansabiopharma.com

Hansa Biopharma AB (publ), a biopharmaceutical company, develops immunomodulatory treatments for enabling transplants and rare immunoglobulin G (IgG)-mediated autoimmune conditions, gene therapy, and cancer using its proprietary enzyme technology platform. The company’s lead drug candidate is Imlifidase, an antibody cleaving enzyme therapy that is in phase 3 clinical trial for use in sensitized kidney transplantations patients, as well as for anti-GBM antibody disease; and phase 2 clinical trial for antibody-mediated kidney transplant rejection and Guillain Barré syndrome. It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases, transplantation, and oncology; and Enzyme based antibody Enhancement (EnzE), which is cancer immunotherapy.

Hansa Biopharma AB (publ) Fundamentals Summary

How do Hansa Biopharma's earnings and revenue compare to its market cap?
HNSA fundamental statistics
Market Capkr3.68b
Earnings (TTM)-kr620.27m
Revenue (TTM)kr77.02m

47.8x

P/S Ratio

-5.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
HNSA income statement (TTM)
Revenuekr77.02m
Cost of Revenuekr27.67m
Gross Profitkr49.35m
Other Expenseskr669.62m
Earnings-kr620.27m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

Oct 20, 2022

Earnings per share (EPS)-13.91
Gross Margin64.08%
Net Profit Margin-805.32%
Debt/Equity Ratio0%

How did HNSA perform over the long term?

See historical performance and comparison